(KAP la SIZ ue mab)
Trade Name(s): Cablivi®
Caplacizumab-yhdp is the generic name for the trade name drub Cablivi®. In some cases, health care professionals may use the trade name Cablivi® when referring to the generic drug name Caplacizumab-yhdp.
Drug Type: Caplacizumab-yhdp is a protein that helps to prevent the formation of blood clots. This medication is classified as a "monoclonal antibody" (for more detail, see "How Caplacizumab-yhdp Works" below).
What Caplacizumab-yhdp Is Used For
- Caplacizumab-yhdp is used for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP - a condition that causes low platelets).
- Caplacizumab-yhdp should be used in combination with plasma exchange and immunosuppressive therapy.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How Caplacizumab-yhdp Is Given
- Caplacizumab-yhdp may be given by intravenous (into the vein) and subcutaneous (the layer between the skin and muscle) injection.
- The first dose will usually be given intravenously and subsequent doses will be given subcutaneously.
- Caplacizumab-yhdp will be given following plasma exchange. Your doctor will determine your exact schedule.
Important things to remember about the side effects of Caplacizumab-yhdp:
- Most people will not experience all of the side effects listed.
- Side effects are often predictable in terms of their onset, duration and severity.
- Side effects will improve after therapy is complete.
- Caplacizumab-yhdp side effects may be quite manageable. There are many options to minimize or prevent the side effects of Caplacizumab-yhdp.
The following side effects are common (occurring in greater than 30%) for patients taking Caplacizumab-yhdp:
These are less common side effects (occurring in 10-29%) for patients receiving Caplacizumab-yhdp:
Not all side effects are listed above. Side effects that are very rare -- occurring in less than about 10 percent of patients -- are not listed here. But you should always inform your health care provider if you experience any unusual symptoms.
When to Contact Your Doctor or Health Care Provider
Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:
- Fever of 100.4º F (38º C) or higher, chills (possible signs of infection)
- Shortness of breath
- Bleeding that does not stop after applying pressure for a few minutes
The following symptoms require medical attention, but are not an emergency. Contact your health care provider within 24 hours of noticing any of the following:
- Nausea (interferes with ability to eat and unrelieved with prescribed medication)
- Vomiting (vomiting more than 4-5 times in a 24-hour period)
- Diarrhea (4-6 episodes in a 24-hour period)
- Unusual bleeding or bruising
- Black or tarry stools, or blood in your stools
- Blood in the urine
- Pain or burning with urination
- Extreme fatigue (unable to carry on self-care activities)
Always inform your health care provider if you experience any unusual symptoms.
- Before starting Caplacizumab-yhdp treatment, make sure you tell your doctor about any other medications you are taking (including prescriptions, over-the-counter, vitamins, herbal remedies, etc.). Do not take aspirin, products containing aspirin unless your doctor specifically permits this.
- Do not receive any kind of immunization or vaccination without your doctor's approval while taking Caplacizumab-yhdp.
- Inform your health care professional if you are pregnant, may be pregnant, or breastfeeding prior to starting this treatment.
- Ask your doctor before engaging in contact sports or activities that could cause injury.
- Use an electric razor and a soft toothbrush to minimize bleeding. In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
- Get plenty of rest.
- Maintain good nutrition.
- Remain active as you are able. Gentle exercise is encouraged such as a daily walk.
- If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.
Monitoring and Testing While Taking Caplacizumab-yhdp
You will be checked regularly by your doctor while you are taking Caplacizumab-yhdp, to monitor side effects and check your response to therapy. Periodic blood work will be obtained to monitor your complete blood count (CBC) as well as the function of other organs (such as your kidneys and liver) will also be ordered by your doctor.
How Caplacizumab-yhdp Works
Caplacizumab-yhdp is classified as a monoclonal antibody. Monoclonal antibodies are a relatively new type of "targeted" cancer therapy.
Antibodies are an integral part of the body's immune system. Normally, the body creates antibodies in response to an antigen (such as a protein in a germ) that has entered the body. The antibodies attach to the antigen in order to mark if for destruction by the immune system.
To make monoclonal antibodies in the laboratory, scientists analyze specific antigens on the surface of cells (the targets). Then, using animal and human proteins, they create a specific antibody that will attach to the target antigen on the cell. When given to the patient, these monoclonal antibodies will attach to matching antigens like a key fits a lock. Since monoclonal antibodies target only specific cells, they may cause less toxicity to healthy cells.
Caplacizumab-yhdp works by targeting von Willebrand factor (vWF) which is a protein that is involved in the process of blood clotting. This blocks the interaction between von Willebrand factor and platelets, which decreases the formation of blood clotting.
Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educational, but is not a substitute for medical advice.